Monopar Therapeutics (MNPR) Shares Outstanding (2016 - 2025)

Monopar Therapeutics has reported Shares Outstanding over the past 10 years, most recently at $6.7 million for Q4 2025.

• Shares Outstanding reached $6.7 million in Q4 2025 per MNPR's latest filing, roughly flat from $6.7 million in the prior quarter.
• Across five years, Shares Outstanding topped out at $17.6 million in Q2 2024 and bottomed at $2.6 million in Q4 2022.
• Median Shares Outstanding over the past 5 years was $6.4 million (2025), compared with a mean of $7.9 million.
• The largest annual shift saw Shares Outstanding plummeted 79.45% in 2022 before it soared 533.25% in 2024.
• Over 5 years, Shares Outstanding stood at $12.6 million in 2021, then tumbled by 79.45% to $2.6 million in 2022, then increased by 15.12% to $3.0 million in 2023, then skyrocketed by 104.72% to $6.1 million in 2024, then grew by 9.66% to $6.7 million in 2025.
• Business Quant data shows Shares Outstanding for MNPR at $6.7 million in Q4 2025, $6.7 million in Q3 2025, and $6.1 million in Q2 2025.

Peer Comparison